Skin Biopsies Identified as Mitochondrial Disease Diagnostic
Researchers confirmed that skin cell testing can accurately diagnose rare mitochondrial disorders.
Updated on Oct. 6, 2026 in Life Sciences
Live Poll
Should medical institutions prioritize functional skin biopsies over invasive diagnostic procedures for rare diseases?
A global study published in EMBO Molecular Medicine has validated that analyzing fibroblasts from skin biopsies provides an effective way to diagnose mitochondrial disease. This approach offers a less invasive alternative to traditional testing methods like liver or muscle tissue collection.
Why it matters
Current genetic testing often yields inconclusive results due to variants of uncertain significance, leaving many patients without a clear diagnosis. This functional testing method helps clinicians bypass those ambiguities by directly measuring cellular performance.
The study utilized fibroblast samples from 30 medical centers across North America, Europe, Australia, and New Zealand to measure mitochondrial performance. Genetic testing currently fails to identify a definitive cause in 35% to 50% of cases.
The players
Children's Hospital Colorado
This facility served as the primary research site for the investigation into mitochondrial diagnostics.
University of Colorado Anschutz
This institution functioned as a co-lead research partner in the development of the fibroblast diagnostic method.
The details
Researchers measured mitochondrial performance inside fibroblasts grown from skin samples to distinguish between affected patients and those without the disease. This method standardizes functional testing across international medical centers to reduce reliance on invasive procedures.
Timeline
The research findings were published online on October 6, 2026.
The Big Picture
This study updates the diagnostic standard set by the clinical use of muscle and liver biopsies for mitochondrial diagnosis by proving skin fibroblasts provide sufficient data. The findings shift the field toward minimally invasive procedures, unlocking new possibilities for early disease detection.
This diagnostic method could soon lead to shorter wait times for patients seeking a definitive diagnosis for rare disorders. It also significantly lowers the physical risk and recovery time for individuals by eliminating the need for surgical muscle or liver tissue collection.
The takeaway
Using skin biopsies to assess mitochondrial function creates a much safer diagnostic pathway for patients suffering from unexplained symptoms. This shift reduces the medical burden on patients while maintaining the high clinical accuracy required for rare disease identification.
Further reading
For more on the latest breakthroughs in clinical diagnostics, visit the Life Sciences section.
More information
Read the full study published in EMBO Molecular Medicine for detailed methodology.
Source note: This article includes information reported by News-Medical.
Live Poll
Should medical institutions prioritize functional skin biopsies over invasive diagnostic procedures for rare diseases?
